Detalhe da pesquisa
1.
A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Neurobiol Dis
; 159: 105507, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34509608
2.
Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease.
Hum Mol Genet
; 28(19): 3244-3254, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31261387
3.
TMEM175 deficiency impairs lysosomal and mitochondrial function and increases α-synuclein aggregation.
Proc Natl Acad Sci U S A
; 114(9): 2389-2394, 2017 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28193887
4.
Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells.
J Neurosci
; 35(42): 14234-50, 2015 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26490863
5.
Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors.
Bioorg Med Chem Lett
; 26(11): 2631-5, 2016 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27106707
6.
Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function.
J Neurochem
; 128(4): 536-46, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24117685
7.
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose Projections.
ACS Med Chem Lett
; 15(1): 123-131, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38229758
8.
Pyrazole Ureas as Low Dose, CNS Penetrant Glucosylceramide Synthase Inhibitors for the Treatment of Parkinson's Disease.
ACS Med Chem Lett
; 14(2): 146-155, 2023 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36793422
9.
Discovery of MK-8768, a Potent and Selective mGluR2 Negative Allosteric Modulator.
ACS Med Chem Lett
; 14(8): 1088-1094, 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37583812
10.
Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.
J Neurogenet
; 25(4): 140-51, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22077787
11.
Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model.
PLoS One
; 16(6): e0252325, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34106956
12.
Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology.
Neurobiol Dis
; 36(1): 96-102, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19595768
13.
A highly reproducible rotenone model of Parkinson's disease.
Neurobiol Dis
; 34(2): 279-90, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19385059
14.
Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease.
J Alzheimers Dis
; 15(1): 97-107, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18780970
15.
Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism.
FASEB J
; 20(13): 2302-12, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17077307
16.
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
J Med Chem
; 60(7): 2983-2992, 2017 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-28245354
17.
Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.
Neurotoxicology
; 25(5): 761-9, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15288507
18.
Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of alpha-synuclein.
J Neurochem
; 96(4): 950-9, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16412098